4-Imidazo[1,2-a]pyridin-7-yl-benzaldehyde | 622402-35-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Imidazo[1,2-a]pyridin-7-yl-benzaldehyde
• 英文别名: 4-Imidazo[1,2-a]pyridin-7-ylbenzaldehyde
• CAS: 622402-35-1
• 化学式: C₁₄H₁₀N₂O
• 分子量: 222.246
• InChiKey: AFQIVTJZQRBRJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Imidazo[1,2-a]pyridin-7-yl-benzaldehyde 在 2,6-二甲基吡啶 、 六氟异丙醇 、 potassium acetate 、 palladium diacetate 、 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.17h， 生成 2-Methyl-4-[7-(4-piperazin-2-ylphenyl)imidazo[1,2-a]pyridin-3-yl]quinoline
  参考文献：
  名称：

  Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors

  摘要：

  The activin-like kinases are a family of kinases that play important roles in a variety of disease states. Of this class of kinases, ALK2, has been shown by a gain-of-function to be the primary driver of the childhood skeletal disease fibrodysplasia ossificans progressiva (FOP) and more recently the pediatric cancer diffuse intrinsic pontine glioma (DIPG). Herein, we report our efforts to identify a novel imidazo[1,2-a]pyridine scaffold as potent inhibitors of ALK2 with good in vivo pharmacokinetic properties suitable for future animal studies.

  DOI：

  10.1016/j.bmcl.2020.127418
• 作为产物：
  描述：

  N-(4-碘-2-吡啶基)-氨基甲酸叔丁酯 在 盐酸 、 四(三苯基膦)钯 、 碳酸氢钠 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 生成 4-Imidazo[1,2-a]pyridin-7-yl-benzaldehyde
  参考文献：
  名称：

  Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

  摘要：

  3,7-Diaryl substituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.007

文献信息

• Tyrosine kinase inhibitors
  申请人：Bilodeau T. Mark

  公开号：US20050176753A1

  公开（公告）日：2005-08-11

  The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及一种咪唑吡啶化合物，其可以抑制、调节和/或调节酪氨酸激酶信号转导，包含这些化合物的组合物以及使用它们治疗哺乳动物中的酪氨酸激酶依赖性疾病和病状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、年龄相关性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
• Inhibition of BMP signaling, compounds, compositions and uses thereof
  申请人：Vanderbilt University

  公开号：US10745400B2

  公开（公告）日：2020-08-18

  Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.

  本发明提供了可用作 BMP 信号转导抑制剂的取代咪唑并[1,2-a]吡啶。本发明进一步提供了本发明化合物的药物组合物。本发明还提供了取代的咪唑并[1,2-a]吡啶的医疗用途。
• TYROSINE KINASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1503757A2

  公开（公告）日：2005-02-09
• EP1503757A4
  申请人：——

  公开号：EP1503757A4

  公开（公告）日：2005-11-16
• INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF
  申请人：Vanderbilt University

  公开号：US20190284183A1

  公开（公告）日：2019-09-19

  Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.